219 related articles for article (PubMed ID: 23965899)
21. Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
Benvenuto G; Todeschini P; Paracchini L; Calura E; Fruscio R; Romani C; Beltrame L; Martini P; Ravaggi A; Ceppi L; Sales G; Donati F; Perego P; Zanotti L; Ballabio S; Grassi T; Delle Marchette M; Tognon G; Sartori E; Adorni M; Odicino F; D'Incalci M; Bignotti E; Romualdi C; Marchini S
Int J Cancer; 2020 Jul; 147(2):565-574. PubMed ID: 32096871
[TBL] [Abstract][Full Text] [Related]
22. DNA methylation-based profiling reveals distinct clusters with survival heterogeneity in high-grade serous ovarian cancer.
Wang J; Li J; Chen R; Yue H; Li W; Wu B; Bai Y; Zhu G; Lu X
Clin Epigenetics; 2021 Oct; 13(1):190. PubMed ID: 34645493
[TBL] [Abstract][Full Text] [Related]
23. ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.
Nadaraja S; Schledermann D; Herrstedt J; Østrup O; Ditzel HJ;
Acta Oncol; 2020 Jan; 59(1):40-47. PubMed ID: 31478407
[No Abstract] [Full Text] [Related]
24. A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?
Lawson BC; Euscher ED; Bassett RL; Liu J; Ramalingam P; Zhong Y; Fleming ND; Malpica A
Am J Surg Pathol; 2020 Feb; 44(2):206-213. PubMed ID: 31651523
[TBL] [Abstract][Full Text] [Related]
25. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
26. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
[TBL] [Abstract][Full Text] [Related]
27. High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
Hollis RL; Churchman M; Michie CO; Rye T; Knight L; McCavigan A; Perren T; Williams ARW; McCluggage WG; Kaplan RS; Jayson GC; Oza A; Harkin DP; Herrington CS; Kennedy R; Gourley C
Cancer; 2019 Aug; 125(16):2772-2781. PubMed ID: 31154673
[TBL] [Abstract][Full Text] [Related]
28. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
[TBL] [Abstract][Full Text] [Related]
29. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
[TBL] [Abstract][Full Text] [Related]
30. Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan.
Kang JH; Lai YL; Cheng WF; Kim HS; Kuo KT; Chen YL; Lee YY
Sci Rep; 2020 Nov; 10(1):20012. PubMed ID: 33203969
[TBL] [Abstract][Full Text] [Related]
31. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
[TBL] [Abstract][Full Text] [Related]
32. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
34. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
35. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
36. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
[TBL] [Abstract][Full Text] [Related]
37. Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior.
Reyes HD; Devor EJ; Warrier A; Newtson AM; Mattson J; Wagner V; Duncan GN; Leslie KK; Gonzalez-Bosquet J
Sci Rep; 2019 Nov; 9(1):17996. PubMed ID: 31784612
[TBL] [Abstract][Full Text] [Related]
38. Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study.
Liu R; Hu R; Zeng Y; Zhang W; Zhou HH
EBioMedicine; 2020 Jan; 51():102602. PubMed ID: 31911269
[TBL] [Abstract][Full Text] [Related]
39. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
Hillman RT; Chisholm GB; Lu KH; Futreal PA
J Natl Cancer Inst; 2018 Mar; 110(3):265-72. PubMed ID: 29584920
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
Böhm S; Faruqi A; Said I; Lockley M; Brockbank E; Jeyarajah A; Fitzpatrick A; Ennis D; Dowe T; Santos JL; Cook LS; Tinker AV; Le ND; Gilks CB; Singh N
J Clin Oncol; 2015 Aug; 33(22):2457-63. PubMed ID: 26124480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
